Bevacizumab Induction
Cross-source consensus on Bevacizumab Induction from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Dosage & preparation
Highlighted claims
- Bevacizumab is an anti-VEGF antibody. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- The induction group receives two 28-day cycles of paclitaxel plus bevacizumab before switching to atezolizumab plus nab-paclitaxel. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- During induction, paclitaxel is given at 90 mg/m2 on days 1, 8, and 15 of each 28-day cycle. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- During induction, bevacizumab is given at 10 mg/kg on days 1 and 15 of each induction cycle. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- The trial tests whether bevacizumab plus paclitaxel first can reduce VEGF-mediated resistance before atezolizumab plus nab-paclitaxel. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)
- Bevacizumab plus paclitaxel is already a standard treatment option for metastatic triple-negative breast cancer regardless of PD-L1 status. — Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)